MODL-22. DEVELOPING A REAL-TIME PERSONALIZED DRUG TESTING PLATFORM FOR PEDIATRIC CNS CANCERS

Abstract INTRODUCTION The relatively small size of biopsied CNS tumors has presented a historical challenge for real-time drug screens. Moreover, in vivo assessment of drug response does not often benefit patients with aggressive gliomas given the relatively long time (>8 months) of tumor engraft...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2020-12, Vol.22 (Supplement_3), p.iii415-iii415
Hauptverfasser:	Laternser, Sandra, Cosentino, Chiara Cianciolo, Przystal, Justyna M, Dettwiler, Susanne, Rushing, Elisabeth Jane, Gerber, Nicolas U, Stücklin, Ana Guerreiro, Prasad, Rachna, Grotzer, Michael, Krayenbühl, Niklaus, Müller, Sabine, Nazarian, Javad
Format:	Artikel
Sprache:	eng
Schlagworte:	Preclinical Models/Experimental Therapy/Drug Discovery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract INTRODUCTION The relatively small size of biopsied CNS tumors has presented a historical challenge for real-time drug screens. Moreover, in vivo assessment of drug response does not often benefit patients with aggressive gliomas given the relatively long time (>8 months) of tumor engraftment in the classic mouse PDX models. Here, we aimed to develop an innovative real-time in vivo and in vitro drug screening platform capable of analyzing a minimal number (
ISSN:	1522-8517 1523-5866
DOI:	10.1093/neuonc/noaa222.595